Zevra Therapeutics Announces Top-Line Data from the Phase 2

KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study ...

Related Keywords

United States , Christopher Drake , Neil Mcfarlane , Nichol Ochsner , Ignacio Guerrero Ros , Adannag Alexander , Linkedin , Zevra Therapeutics Inc , Us Drug Enforcement Agency , Drug Administration , Exchange Commission , Twitter , Epworth Sleepiness Scale , Idiopathic Hypersomnia Severity Scale , Sleep Inertia Visual Analog Scale , Principal Investigator , Chief Executive Officer , Brain Fog , Idiopathic Hypersomnia , Orphan Drug Designation , Enforcement Agency , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Nasdaq Zvra , Zevra Therapeutics ,